To whom recommend intensive treatment for hypertension?

European Heart Journal Supplements : Journal of the European Society of Cardiology
Massimo Volpe, Giovanna Gallo

Abstract

Arterial hypertension is the main identifiable cardiovascular risk factor, and although the benefit of blood pressure reduction is universally acknowledged, the scientific community has long been divided over the therapeutic blood pressure targets to be reached, also considering the estimated overall cardiovascular risk and the presence of individual risk factors and associated comorbidities. During the last few years, numerous clinical studies and meta-analyses, in particular, the SPRINT study, have been published, demonstrating the advantages of an intensive antihypertensive treatment, over a target blood pressure value (<140/90 mmHg), in the reduction of major cardiovascular events, myocardial infarction, stroke, heart failure, and all-causes cardiovascular mortality. Stemming from these results the major International Guidelines revisited the therapeutic objectives, recommending blood pressure value <130/80 mmHg for the vast majority of hypertensive patients until the age of 65 and suggesting a reduction of the target also in the elderly. Numerous studies and meta-analyses demonstrated that the reduction of the risk of coronary or cerebral events, and of all-causes cardiovascular mortality, is independent from the baseline ...Continue Reading

References

Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Aug 15, 2006·Journal of the American College of Cardiology·Ilke SipahiSteven E Nissen
Jul 12, 2007·The American Journal of Cardiology·William C CushmanUNKNOWN ACCORD Study Group
Apr 2, 2008·The New England Journal of Medicine·Nigel S BeckettUNKNOWN HYVET Study Group
Jan 14, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·UNKNOWN JATOS Study Group
Jun 10, 2010·Hypertension·Toshio OgiharaUNKNOWN Valsartan in Elderly Isolated Systolic Hypertension Study Group
Jun 5, 2013·The Journal of Clinical Hypertension·Yong WeiJiguang Wang
May 20, 2016·JAMA : the Journal of the American Medical Association·Jeff D WilliamsonUNKNOWN SPRINT Research Group
Feb 6, 2017·Journal of the American College of Cardiology·Chirag BavishiFranz H Messerli
Apr 30, 2017·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeGiuliano Tocci
May 12, 2017·Nature Reviews. Cardiology·Gema Ruiz-HurtadoLuis M Ruilope
Jun 22, 2017·Circulation·Gabriel S TajeuPaul Muntner
Dec 24, 2017·International Journal of Cardiology·Massimo VolpeGiuliano Tocci
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Citations

Jan 4, 2021·Atencion primaria·Domingo Orozco-BeltránJorge Navarro Pérez

❮ Previous
Next ❯

Software Mentioned

SPRINT SENIOR
HYVET

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Related Papers

Schweizerische medizinische Wochenschrift
T F LüscherG Noll
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension
Michael A Weber
© 2022 Meta ULC. All rights reserved